# A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

Source: https://onco.cc/trials/nct05061134/  
OnCo record `nct05061134` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ceralasertib, Durvalumab in melanoma, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition is a phase 2 interventional study registered as NCT05061134 by AstraZeneca, with 194 participants enrolled, started 2022-08-11 and due to reach its primary completion in 2024-04-12. Interventions recorded: Ceralasertib, Durvalumab. Conditions listed: Melanoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: MONETTE
- Tags: ctgov-ingest
- Registry id: NCT05061134
- Phase: 2
- Setting: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition
- Sponsor: AstraZeneca
- Enrolled: 194
- Outcomes: Main Study: Objective Response Rate (ORR): Main Study: Ceralasertib + Durvalumab 9.3% vs Main Study: Ceralasertib Monotherapy 5.8%; Main Study and Biopsy Study: Overall Survival (OS): Main Study: Ceralasertib + Durvalumab 16 months vs Main Study: Ceralasertib Monotherapy 12.32 months vs Biopsy Study: Ceralasertib + Durvalumab; Main Study and Biopsy Study: Progression Free Survival (PFS): Main Study: Ceralasertib + Durvalumab 2 months vs Main Study: Ceralasertib Monotherapy 1.94 months vs Biopsy Study: Ceralasertib + Durvalumab 2.83 months

## Sources

- ClinicalTrials.gov NCT05061134: https://clinicaltrials.gov/study/NCT05061134

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Ceralasertib](https://onco.cc/drugs/ceralasertib/), [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05061134.json